Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Byrd

Showing results (631-640 of 1,058) with videos related to

Pageof 106
Sort By:
Leukemia|February 25, 2015
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemiaJ Flynn, J Jones, A J Johnson, et al.
Leukemia & Lymphoma|August 13, 2021
Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphomaJennifer Woyach, Alessandra Tedeschi, Talha Munir, et al.
Leukemia|August 17, 2024
Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiationJohn Alan Gambril, Sanam M Ghazi, Stephen Sansoterra, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 25, 2019
T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple MyelomaFabienne Lucas, Michael Pennell, Ying Huang, et al.
Leukemia|March 18, 2023
Evaluation of bleeding events in patients receiving acalabrutinib therapyPooja S Kumar, Tracy Wiczer, Lindsay Rosen, et al.
Leukemia|May 25, 2023
Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapyPooja S Kumar, Tracy Wiczer, Lindsay Rosen, et al.
Hepatology (Baltimore, Md.)|March 11, 2011
Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinomaHany A Omar, Chih-Chien Chou, Lisa D Berman-Booty, et al.
Cancer Research|April 3, 2004
Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targetsLaura J Rush, Aparna Raval, Pauline Funchain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2023
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib TherapyJennifer A Woyach, Paolo Ghia, John C Byrd, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 7, 2001
IL-13-mediated worm expulsion is B7 independent and IFN-gamma sensitiveJ Urban, H Fang, Q Liu, et al.
Pageof 106

Showing results (631-640 of 1,058) with videos related to

Sort By:
Pageof 106
Leukemia|February 25, 2015
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemiaJ Flynn, J Jones, A J Johnson, et al.
Leukemia & Lymphoma|August 13, 2021
Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphomaJennifer Woyach, Alessandra Tedeschi, Talha Munir, et al.
Leukemia|August 17, 2024
Atrial fibrillation burden and clinical outcomes following BTK inhibitor initiationJohn Alan Gambril, Sanam M Ghazi, Stephen Sansoterra, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 25, 2019
T Cell Transcriptional Profiling and Immunophenotyping Uncover LAG3 as a Potential Significant Target of Immune Modulation in Multiple MyelomaFabienne Lucas, Michael Pennell, Ying Huang, et al.
Leukemia|March 18, 2023
Evaluation of bleeding events in patients receiving acalabrutinib therapyPooja S Kumar, Tracy Wiczer, Lindsay Rosen, et al.
Leukemia|May 25, 2023
Correction: Evaluation of bleeding events in patients receiving acalabrutinib therapyPooja S Kumar, Tracy Wiczer, Lindsay Rosen, et al.
Hepatology (Baltimore, Md.)|March 11, 2011
Antitumor effects of OSU-2S, a nonimmunosuppressive analogue of FTY720, in hepatocellular carcinomaHany A Omar, Chih-Chien Chou, Lisa D Berman-Booty, et al.
Cancer Research|April 3, 2004
Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targetsLaura J Rush, Aparna Raval, Pauline Funchain, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2023
B-cell Receptor Pathway Mutations Are Infrequent in Patients with Chronic Lymphocytic Leukemia on Continuous Ibrutinib TherapyJennifer A Woyach, Paolo Ghia, John C Byrd, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 7, 2001
IL-13-mediated worm expulsion is B7 independent and IFN-gamma sensitiveJ Urban, H Fang, Q Liu, et al.
Pageof 106